3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other
2
Head & Neck
2
Conditions
Lymphoma
3
Stomatitis
2
Small Cell Lung Carcinoma
2
Neoplasms
2
Mucositis
2
Mouth Neoplasms
2
Lung Neoplasms
2
Head and Neck Neoplasms
2
Carcinoma, Small Cell
2
Brain Neoplasms
2
Spinal Cord Neoplasms
1
Neuroendocrine Tumors
1
Neoplasm Metastasis
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Radiotherapy
9
Cisplatin
8
Fibroblast Growth Factor 7
6
Low-Level Light Therapy
5
angiotensin I (1-7)
4
Radiation
4
Injections
4
Propolis
3
Morphine
3
Methotrexate
3
Leucovorin
3
Drug Therapy
3
Cryotherapy
3
glucarpidase
2
aluminum hydroxide, magnesium hydroxide, drug combination
2
Xylitol
2
Water
2
Radiotherapy, Intensity-Modulated
2
RRx-001
2
Probiotics
2
Pentoxifylline
2
Mouthwashes
2
Melphalan
2
Lidocaine
2
Ketamine
2
Interleukin 1 Receptor Antagonist Protein
2
Honey
2
Glutamine
2
Gabapentin
2
Fluorouracil
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Mucositis
×
RRx-001
×
Clear all
NCT05966194
2024-11-15
KEVLARx
EpicentRx, Inc.
Phase 2
Recruiting
216 enrolled
NCT03515538
2024-11-04
PREVLAR
EpicentRx, Inc.
Phase 2
Completed
53 enrolled
15 charts